Company: STAA
Filing Date: 2025-09-15
Form Type: PREC14A
Source: 0001213900-25-087448
Chunk: 11

Company: STAAR SURGICAL CO
Filing Date: 2025-09-15
Form: PREC14A
Chunk 11
---
-surgical/investors/quarter-report/staar-surgical-costaa-us-q1-2025-earnings-call-07052025.pdf 
 (May 7, 2025).                                                                                                                                     |

| 21 | Id. |

| 23 | Id. |

| 25 | Id. |

| 28 | Id. |

| 29 | See id. at 40. |

<div align='center'>6</div>

On the Company’s earnings
call in May 2025, the Company’s CEO proclaimed that “better days are ahead”30
for the Company. We agree.

Over the last few months,
the Company has taken actions to meaningfully reduce expenses and has been working with its distributors to manage inventory levels and
mitigate the impact of tariffs.31 With ICL
demand in China “getting stronger,”32
we believe the Company will quickly return to revenue growth and accelerated profitability which, in turn, we expect to drive greater
value for stockholders.

As STAAR’s largest stockholder,
if the Proposed Merger is defeated—as we believe it should be—we are prepared to support the Company with the recruiting and
nomination of new directors and executives, if necessary, to ensure that the Company fulfills its promise to patients, employees, business
partners and stockholders.

The uncompelling Merger Agreement
Proposal before stockholders today appears to us to be the result of suboptimal timing and a flawed process, and the price appears to
reflect near-term pessimism and market dynamics rather than the Company’s intrinsic value. We are confident that STAAR can deliver
near-term value to stockholders far in excess of the $28 per share that Alcon is offering and that, in the long term, the Company can
build upon that value as it delivers on the promise of its unique technology and assets.

We oppose the Proposed Merger
on that basis and urge other stockholders to join us in doing so by voting “AGAINST” the Merger Agreement Proposal
on the GREEN Proxy Card.

Vote Required

According to the Company’s
proxy statement, the approval of the Merger Agreement Proposal requires the affirmative vote of the holders of a majority of the outstanding
shares of Common Stock entitled to vote thereon. If a quorum is present, abstentions and “broker non-votes” will
have the same effect as a vote “AGAINST” the Merger Agreement Proposal. Nevertheless, we urge stockholders to vote “ AGAINST” the Merger Agreement